Literature DB >> 18062791

Mortality rates in patients with Barrett's oesophagus.

P Moayyedi1, N Burch, N Akhtar-Danesh, S K Enaganti, R Harrison, N J Talley, J Jankowski.   

Abstract

BACKGROUND: Patients with Barrett's oesophagus are at increased risk of oesophageal adenocarcinoma. Observational studies have suggested increase in overall mortality also but data are conflicting. AIM: To assess the cause of death in patients with Barrett's oesophagus compared with the general population.
METHODS: Patients with Barrett's oesophagus were identified retrospectively in four hospitals in Leicestershire, UK using electronic endoscopy and histopathology records from 1997 to 2003. Data on deaths from this cohort of patients were identified through the Office of National Statistics and compared with age- and gender-adjusted mortality in the Leicestershire region. RESULT: In all, 1272 Barrett's patients were identified with 245 deaths in this cohort. Overall mortality was found to be increased [male standardized mortality ratio (SMR) = 552, 95% CI = 466-638; female SMR 455, 95% CI = 357-552]. The main disease areas that were responsible for this increase were oesophageal adenocarcinoma (n = 25, male SMR = 2171, 95% CI = 991-3351; female SMR = 1300, 95% CI = 26-2574), bronchopneumonia (n = 70, male SMR = 146, 95% CI = 55-236; female SMR = 436, 95% CI = 272-601) and ischaemic heart disease (n = 51, male SMR = 186, 95% CI = 97-2748; female SMR = 205, 95% CI = 105-306).
CONCLUSIONS: Patients with Barrett's oesophagus die more commonly of bronchopneumonia and ischaemic heart disease compared with oesophageal adenocarcinoma, and overall mortality in this group may be increased.

Entities:  

Mesh:

Year:  2007        PMID: 18062791     DOI: 10.1111/j.1365-2036.2007.03582.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  31 in total

Review 1.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  Barrett esophagus and life expectancy: implications for screening?

Authors:  Ernst J Kuipers
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

3.  Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves.

Authors:  Gary W Falk
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

4.  The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort.

Authors:  B T Theron; H Padmanabhan; H Aladin; P Smith; E Campbell; P Nightingale; B T Cooper; N J Trudgill
Journal:  United European Gastroenterol J       Date:  2016-02-19       Impact factor: 4.623

5.  New strategies in Barrett's esophagus: integrating clonal evolutionary theory with clinical management.

Authors:  Brian J Reid; Rumen Kostadinov; Carlo C Maley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

Review 6.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 7.  Genetic Insights in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Brian J Reid; Thomas G Paulson; Xiaohong Li
Journal:  Gastroenterology       Date:  2015-07-21       Impact factor: 22.682

8.  Evolving changes in the management of early oesophageal adenocarcinoma in a tertiary centre.

Authors:  N J O'Farrell; J V Reynolds; N Ravi; J O Larkin; V Malik; G F Wilson; C Muldoon; D O'Toole
Journal:  Ir J Med Sci       Date:  2012-12-16       Impact factor: 1.568

9.  Barrett's esophagus: where do we stand?

Authors:  Majid A Al Madi
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

10.  A 52-year-old man with heartburn: should he undergo screening for Barrett's esophagus?

Authors:  Seth D Crockett; A Sidney Barritt; Nicholas J Shaheen
Journal:  Clin Gastroenterol Hepatol       Date:  2009-12-03       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.